key: cord-0877311-9h5k33gu
authors: Li, Yong; Zhao, Kun; Wei, Hongcheng; Chen, Wensen; Wang, Wei; Jia, Ling; Liu, Qiongfang; Zhang, Jinpeng; Shan, Tao; Peng, Zhihang; Liu, Yun; Yan, Xiaoxiang
title: Dynamic relationship between D‐dimer and COVID‐19 severity
date: 2020-05-18
journal: Br J Haematol
DOI: 10.1111/bjh.16811
sha: 560c1adf9cace75920a8cc6b369aaad24b2ed478
doc_id: 877311
cord_uid: 9h5k33gu

Since December 2019, the seriousness of coronavirus disease 2019 (COVID‐19) pandemic has been on escalation (Lu, et al 2020). Coagulopathy is common in critically ill patients with COVID‐19 (Tang, et al 2020b). Systemic microvascular thrombosismay occur in most deaths, which was further identified by a recent autopsy (Luo 2020). However, less has been known about the coagulation parameter D‐dimer in the progression of COVID‐19. In this study, we describe 279 COVID‐19 patients recruited from three hospitals in Hubei Province, China, and then investigate the dynamic relationship between D‐dimer level and the progression of COVID‐19.

This article is protected by copyright. All rights reserved Letter to the editor： Since December 2019, the seriousness of coronavirus disease 2019 (COVID-19) pandemic has been on escalation (Lu, et al 2020) . Coagulopathy is common in critically ill patients with COVID-19 (Tang, et al 2020b) . Systemic microvascular thrombosismay occur in most deaths, which was further identified by a recent autopsy (Luo 2020) . However, less has been known about the coagulation parameter D-dimer in the progression of COVID-19. In this study, we describe 279 COVID-19 patients recruited from three hospitals in Hubei Province, China, and then investigate the dynamic relationship between D-dimer level and the progression of COVID-19.

According to COVID-19 Diagnosis and Treatment Scheme (Trial Version 7) (Commission 2020) , all laboratory-confirmed COVID-19 patients were mild and moderate cases on admission in our study. We further divided them into three groups according to their clinical courses: ordinary group (disease was mild or subsided, n=136); improved group (disease worsened first and was then improved gradually after treatment, n=23); poor group (disease deteriorated and deaths, n=120). On admission, the epidemiological data, comorbidities, and clinical symptoms of patients were obtained (Table 1 ). Then, we tested coagulation profile for ten consecutive days since admission. Table 1 Infection-induced coagulopathy and secondary hyper-fibrinolysis has been identified in severe cases of COVID-19 (Ji, et al 2020) . As well, higher D-dimer level on admission was related to a worse prognosis of COVID-19 (Zhou, et al 2020) . Thus, we tracked the variations of D-dimer for ten consecutive days. Based on random forests, Gini index at Day 1 was obviously higher than that at the other days in three groups (Figure 1a) . On admission, D-dimer level was higher in improved and poor groups than that in ordinary group. Then, the level decreased gradually in improved group, but remained high in poor group as the disease deteriorated (Figure 1b) . The results were further adjusted and examined by multinomial logistic regression model. As shown in Figure 1c , on admission, compared with ordinary group, improved group and poor group demonstrated an odds ratio (OR) of 1.42 (95%CI: 1.04, 1.96, p=0.03) and 1.35 (95%CI: 1.02, 1.80, p=0.04), respectively (Table S1). 0.93 (0.78, 1.10) Further, we separated the ten days into three stages: Stage 1, Day 1; Stage 2, Day 2-5; Stage 3, Day 6-10. At Stage 1, OR of ordinary group (0.25 (95% CI: 0.16, 0.37, p<0.001)) was obviously different from that of poor group (0.93 (95%CI: 0.78, 1.10, p=0.37)) (Figure 1d, e) . From Stage 1 to Stage 2, D-dimer level increased with disease progression in poor group (1.60 (95%CI: 1.28, 2.00, p<0.001)), but not in ordinary group (1.19 (95%CI: 0.97, 1.46, p=0.09)) (Figure 1d, e) . The same trend from Stage 2 to Stage 3 was also observed, and the OR of ordinary group and poor group was1.25 (95%CI: 1.07, 1.47, p=0.07), and 1.71 (95%CI: 1.43, 2.05,p<0.001), respectively (Figure   1d , e). The detailed information was shown in Table S2 .

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

Notice on Printing and Distributing the New Coronary Virus Pneumonia Diagnosis and Treatment Plan

How to use D-dimer in acute cardiovascular care

Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility

Diffuse Alveolar Hemorrhage Caused by Warfarin after Rifampicin Discontinuation

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

L (2020) Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19)

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan

Heart rate, median(IQR), bpm

SBP, median(IQR), mm Hg 125 (119-137) is protected by copyright. All rights reserved DBP, median(IQR), mm Hg 78